An Open-Label Pilot Study to Evaluate the Safety and Efficacy of DVX201 NK Cells in Patients With Relapsed or Refractory AML or High Risk MDS or High Risk Overlapping Myelodysplastic / Myeloproliferative Neoplasms
Latest Information Update: 24 Jul 2024
At a glance
- Drugs DVX 201 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Adverse reactions
- Sponsors Coeptis Therapeutics; Deverra Therapeutics
- 19 Jul 2024 Status changed from recruiting to completed.
- 13 Mar 2024 Planned End Date changed from 30 Jun 2023 to 1 Jul 2024.
- 13 Mar 2024 Planned primary completion date changed from 31 Dec 2022 to 1 Jun 2024.